Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication

Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication

Abstract After completion of a 6‐week double‐blind trial of asenapine sublingual tablets (10 or 20 mg/day) versus placebo in Asian patients with acute exacerbation of schizophrenia, including Japanese patients, this open‐label study evaluated the safety and efficacy of a 52‐week treatment with asena...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Toshihiko Kinoshita, Yoshiteru Takekita, Shuichi Hiraoka, Fumihiro Tamura, Yasuhiro Iwama
Natura:	Articolo
Lingua:	English
Pubblicazione:	Wiley 2023-09-01
Serie:	Neuropsychopharmacology Reports
Soggetti:	asenapine clinical trial schizophrenia
Accesso online:	https://doi.org/10.1002/npr2.12342

Documenti analoghi

Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real‐world data
di: Yoshiteru Takekita, et al.
Pubblicazione: (2024-03-01)

Predictors of continuation for asenapine from real-world data in patients with schizophrenia
di: Yoshiteru Takekita, et al.
Pubblicazione: (2024-08-01)

Transdermal Asenapine in Schizophrenia: A Systematic Review
di: Carrithers B, et al.
Pubblicazione: (2020-08-01)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
di: Yuichi Inoue, et al.
Pubblicazione: (2021-05-01)

Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial
di: Shuhei Wada, et al.
Pubblicazione: (2023-03-01)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
di: Okazaki K, et al.
Pubblicazione: (2017-11-01)

Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia
di: Kamiyu Ogyu, et al.
Pubblicazione: (2020-06-01)

Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
di: Durgam S, et al.
Pubblicazione: (2017-07-01)

Asenapine pharmacokinetics and tolerability in a pediatric population
di: Dogterom P, et al.
Pubblicazione: (2018-08-01)

A comparative study of olanzapine versus asenapine in acute treatment of manic episode: A 3-week prospective study
di: Ajeet Sidana, et al.
Pubblicazione: (2014-01-01)

Effect of single-administration of d-sorbitol pretreatment on the bitterness and continued willingness to take asenapine: a randomized, single-blind, placebo-controlled, crossover trial
di: Shuhei Wada, et al.
Pubblicazione: (2024-01-01)

Efficacy of HP-3070, A Once-Daily Asenapine Transdermal System, in the Treatment of Adults with Schizophrenia: A PANSS Five-Factor Analysis
di: Citrome L, et al.
Pubblicazione: (2024-03-01)

Asenapine for bipolar disorder
di: Scheidemantel T, et al.
Pubblicazione: (2015-12-01)

Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder
di: Citrome L, et al.
Pubblicazione: (2017-12-01)

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials
di: Nations Kari R, et al.
Pubblicazione: (2011-06-01)

Boosting the In Vivo Transdermal Bioavailability of Asenapine Maleate Using Novel Lavender Oil-Based Lipid Nanocapsules for Management of Schizophrenia
di: Fatma Sa’eed El-Tokhy, et al.
Pubblicazione: (2023-02-01)

Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study
di: Tomohiko Kimura, et al.
Pubblicazione: (2024-03-01)

Role of sublingual asenapine in treatment of schizophrenia
di: Citrome L
Pubblicazione: (2011-05-01)

The Influence of Long-Term Treatment with Asenapine on Liver Cytochrome P450 Expression and Activity in the Rat. The Involvement of Different Mechanisms
di: Przemysław J. Danek, et al.
Pubblicazione: (2021-06-01)

Validation of an RP-HPLC Method for the Determination of Asenapine Maleate in Dissolution Media and Application to Study In Vitro Release from Co-Crystals
di: Suhair S. Al-Nimry, et al.
Pubblicazione: (2021-03-01)

Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight
di: Findling RL, et al.
Pubblicazione: (2018-08-01)

Eff ect of a single asenapine treatment on Fos expression in the brain catecholamine-synthesizing neurons: impact of a chronic mild stress preconditioning
di: Osacka J., et al.
Pubblicazione: (2017-04-01)

Treatment of 22q11.2 deletion syndrome-associated schizophrenia with comorbid anxiety and panic disorder
di: Candace B. Borders, et al.
Pubblicazione: (2017-10-01)

Long-term sustained release Poly(lactic-co-glycolic acid) microspheres of asenapine maleate with improved bioavailability for chronic neuropsychiatric diseases
di: Junqiu Zhai, et al.
Pubblicazione: (2020-01-01)

Two New HPLC Methods, Assessed by GAPI, for Simultaneous Determination of Four Antipsychotics in Pharmaceutical Formulations: A Comparative Study
di: Eman A. Abdel Hameed, et al.
Pubblicazione: (2022-08-01)

Sublingual asenapine for agitation in malabsorptive states: three patient cases
di: Bradley G. Burk, et al.
Pubblicazione: (2024-07-01)

New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania
di: Warren CG, et al.
Pubblicazione: (2013-05-01)

Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms
di: Yoshiteru Takekita, et al.
Pubblicazione: (2024-12-01)

Exploring peptide dendrimers for intestinal lymphatic targeting: formulation and evaluation of peptide dendrimer conjugated liposomes for enhancing the oral bioavailability of Asenapine maleate
di: Ajjappla Basavaraj Shreya, et al.
Pubblicazione: (2024-11-01)

Still Regarding Schizophrenia, Secondary Schizophrenia, Pseudo-Schizophrenia, and Schizophrenia-Like Psychosis
di: João Gama Marques
Pubblicazione: (2022-06-01)

Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia
di: Yumi Aoki, et al.
Pubblicazione: (2023-09-01)

The effect of eight weeks of Yoga exercise on sustained attention and memory performance in people with Schizophrenia
di: Forozan Ivandar, et al.
Pubblicazione: (2019-07-01)

Evaluating the Effect of 8-Week Treatment With Risperidone On Fasting Blood Glucose of Patients with Schizophrenia
di: Firouzeh Raisi, et al.
Pubblicazione: (2007-09-01)

Evaluating the Effect of 8-Week Treatment With Risperidone On Fasting Blood Glucose of Patients with Schizophrenia
di: Firouzeh Raisi, et al.
Pubblicazione: (2007-08-01)

Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder
di: Ichiro Kusumi, et al.
Pubblicazione: (2018-11-01)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
di: Iyo M, et al.
Pubblicazione: (2021-08-01)

Schizophrenia /
di: Hirsch, Steven R., et al.
Pubblicazione: (2003)

Schizophrenia /
di: 378526 Birchwood, Max, et al.
Pubblicazione: (2001)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
di: Lambert M, et al.
Pubblicazione: (2020-12-01)

Lithium-induced cognitive dysfunction assessed over 1-year hospitalisation: A case report
di: Yuji Murase, et al.
Pubblicazione: (2024-09-01)